| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6edb5285b39ab61950d1341a0eb9045f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2004 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2014-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0227b3e905c7deba39cb502bf9bbf20a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa1d74bf522966cb86f9bd97a972e661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a9b9d72b1a164440d62c424bf01834a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e556d1981ad03e234b6c6925000fed8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef5c82d5ec0e4ba6a4d6678b4aec3c8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3386cc66ae9aaa1d6cc564f2f2e82bc8 |
| publicationDate |
2016-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2968363-A1 |
| titleOfInvention |
Lipobalanced long chain testosterone esters for oral delivery |
| abstract |
The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure wherein R is -C13H25O or -C14H27O. One or both of the esters can be present in the pharmaceutical composition. The composition is formulated such that upon single dose administration to a group of human subject, the composition provides a mean serum testosterone Cavg t12-t24 that is within about 35% to about 70% of the mean serum testosterone Cavg t0-t24. |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |